

**Discussions with leaders:** *JNM* editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Nora Volkow. . . . . **Page 717**

**Medical treatment of GEP NETS:** Mohamed and Strosberg provide an overview of advances in medical management of gastroenteropancreatic neuroendocrine tumors within the context of the larger multidisciplinary approach to these diseases. . . . . **Page 721**

**Imaging the heart–brain axis:** Thackeray offers a look at recent work underlining the still-to-be-elucidated connections between neuroinflammation/long-term brain function and ischemic injury to the heart. . . . . **Page 728**

**Cell therapy imaging:** Martinez and colleagues highlight key developments over the last 5 years in cell-based cancer therapies, including the introduction of novel tracers for in vivo tracking. . . . . **Page 730**

**Imaging agent/modality translation:** Gambhir and other participants report on a 2017 National Cancer Institute–led meeting of government, professional, and industry groups on phase III studies and pathways of approval, coverage, and reimbursement for new cancer imaging agents and modalities. . . . . **Page 736**

**Dynamic PET/CT in PPGLs:** Berkel and colleagues use dynamic  $^{18}\text{F}$ -FDG PET/CT imaging to assess whether in vivo  $^{18}\text{F}$ -FDG pharmacokinetic assessment offers added value over static PET to distinguish different genotypes in pheochromocytomas and paragangliomas. . . . . **Page 745**

**Tumor lysis syndrome after RLT:** Huang and colleagues describe the occurrence of tumor lysis syndrome after radioligand therapy with  $^{177}\text{Lu}$ -labeled agents in patients with neuroendocrine tumors and prostate cancer. . . . . **Page 752**

**Fluorescence-guided surgery:** Liu and Sanai provide perspective on current approaches, trends, and challenges to the clinical adoption of fluorescence-guided surgery and intraoperative decision making and preview a related article in this issue of *JNM*. . . . . **Page 756**

**Real-time fluorescence-guided surgery:** van Keulen and colleagues assess the clinical utility of real-time fluorescence imaging for intraoperative decision

making in patients with head and neck squamous cell carcinoma. . . . . **Page 758**

**Tongue cancer tumor margins:** Meershoek and colleagues explore the utility of an indocyanine green– $^{99\text{m}}\text{Tc}$ -nanocolloid tracer for tumor margin demarcation combined with sentinel node biopsy in patients with oral tongue tumors. . . . . **Page 764**

**Characterizing thyroid cancer:** De Rose and colleagues validate galectin-3 targeting as a method to detect non–radioiodine-avid thyroid cancer in thyroid orthotopic tumor models and discuss potential advantages over thyroid scintigraphy in distinguishing malignant from benign lesions. . . . . **Page 770**

**$^{64}\text{Cu}$ -SARTATE in NETs:** Hicks and colleagues perform a first-in-humans trial of PET/CT imaging with this novel somatostatin analog in patients with neuroendocrine neoplasia to assess its safety and ability to localize disease at early and late imaging time-points. . . . . **Page 777**

**$^{68}\text{Ga}$ -PSMA-11 metaanalysis:** Hope and colleagues detail an updated metaanalysis of reports on  $^{68}\text{Ga}$ -PSMA-11 PET staging in prostate cancer, separating imaging at the time of diagnosis from that at biochemical recurrence and focusing on pathology correlation. . . . . **Page 786**

**PET and MR imaging in PCa:** Emmett and colleagues assess the ability of  $^{18}\text{F}$ -FCH PET/CT,  $^{68}\text{Ga}$ -HBED-CC PSMA-11 PET/CT, and pelvic multiparametric MR imaging to identify men with prostate cancer who will best benefit from salvage radiation treatment. . . . . **Page 794**

**$^{68}\text{Ga}$ -FAPI PET/CT tumor SUV:** Kratochwil and colleagues quantify uptake of a  $^{68}\text{Ga}$ -labeled fibroblast-activation-protein inhibitor on PET/CT in various primary and metastatic tumors to identify the most promising indications for future application. . . . . **Page 801**

**Clinical experience with  $^{90}\text{Y}$ -PSMA:** Rathke and colleagues present dosimetry estimates for  $^{90}\text{Y}$ -labeled prostate-specific membrane antigen–617, report first clinical experiences, and discuss advantages and drawbacks of varying the  $\beta$ -emitter in PSMA-targeting radioligand therapy. . . . . **Page 806**

**Exendin-4 for insulinoma therapy:** Buitinga and colleagues evaluate the ability of succinylated gelatin to reduce renal accumulation of radiolabeled exendin and estimate maximum absorbed

insulinoma doses if exendin were used for peptide-receptor radionuclide therapy. . . . . **Page 812**

**$^{18}\text{F}$ -JK-PSMA-7 for PSMA-positive lesions:** Zlatopolskiy and colleagues describe development of this highly selective prostate-specific membrane antigen probe and its enhanced imaging properties, with comparisons to  $^{18}\text{F}$ -DCFPyL,  $^{18}\text{F}$ -PSMA-1007, and  $^{68}\text{Ga}$ -PSMA-11. . . . . **Page 817**

**Patient positioning for cardiac SPECT:** Perrin and colleagues report on results of a study assessing myocardial perfusion imaging in a forward-leaning bikerlike position with the high-sensitivity D.SPECT cadmium-zinc-telluride camera. . . . . **Page 824**

**Data-driven GPM detection and correction:** Lassen and colleagues investigate the feasibility of an automated data-driven method for detection of gross patient motion during coronary PET acquisition. . . . . **Page 830**

**AD conversion–related network:** Blazhenets and colleagues use a principal components analysis to identify a metabolic Alzheimer disease conversion–related pattern in PET data from individuals with mild cognitive impairment and investigate the prognostic value of resulting pattern expression scores. . . . . **Page 837**

**Reproducibility of awake mouse brain PET:** Miranda and colleagues develop and validate brain PET imaging techniques for awake, freely moving mice, with radioactive point-source markers used to track head motion for correction. . . . . **Page 844**

**MR and PET/MR index in Crohn's disease:** Li and colleagues describe an  $^{18}\text{F}$ -FDG PET/MR enterography index as a hybrid surrogate marker for active ileocolonic inflammation in Crohn's disease and compare its diagnostic performance with that of validated MR indices. . . . . **Page 851**

**Innate immuno-PET in colitis:** Dmochowska and colleagues compare immuno-PET of antibodies to IL-1 $\beta$  and CD11b against standard  $^{18}\text{F}$ -FDG and MR imaging approaches in detection of colonic inflammation. . . . . **Page 858**

**PET radiomics optimization:** Papp and colleagues report on a radiomics analysis of  $^{18}\text{F}$ -FDG PET data to identify feature extraction and imaging protocol parameters that minimize radiomic feature variations across PET imaging systems. . . . . **Page 864**